Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

11.8%

2 terminated out of 17 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

29%

5 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed with results

Key Signals

3 with results71% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (2)
P 2 (3)
P 3 (3)
P 4 (2)

Trial Status

Completed5
Recruiting4
Terminated2
Enrolling By Invitation2
Withdrawn1
Active Not Recruiting1

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT07046494Phase 2RecruitingPrimary

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

NCT07101107Not Yet RecruitingPrimary

Socio-cognitive and Biological Responses to Maltreatment

NCT07239843Enrolling By Invitation

Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders

NCT06740383Recruiting

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

NCT07314190Enrolling By Invitation

Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder

NCT04580134Phase 4Recruiting

CLOZAPINE Response in Biotype-1

NCT07194278Not ApplicableRecruitingPrimary

Feasibility and Preliminary Results of the Efficacy of Blue-Blocking Glasses on Manic Symptoms in Bipolar Disorder

NCT04031469Suspended

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT05400785Not ApplicableCompleted

Efficacy of the Mobile Application for Prediction and Prevention of Mood Episode Recurrence Based on Machine Learning

NCT06608641Phase 3Active Not RecruitingPrimary

Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

NCT00764478Phase 3CompletedPrimary

Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)

NCT03386851Completed

Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 Disorder

NCT03643159Phase 4Terminated

A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

NCT01674010Phase 2TerminatedPrimary

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

NCT01396291Phase 3CompletedPrimary

Efficacy and Safety of Asenapine in the Prevention of Recurrence of Mood Episodes in Participants With Bipolar 1 Disorder (P06384)

NCT01981811Phase 2WithdrawnPrimary

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

NCT02050854CompletedPrimary

Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia

Showing all 17 trials

Research Network

Activity Timeline